• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

    4/22/25 7:30:37 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email

    PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.

    To access the live webcast of BridgeBio's presentation, please visit the "Events" page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.

    Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/682276610.

    About BridgeBio Pharma, Inc.

    BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.

    BridgeBio Contact:

    Bubba Murarka, EVP Communications

    [email protected]

    (650)-789-8220

    Chinmay Shukla, VP Strategic Finance

    [email protected] 



    Primary Logo

    Get the next $BBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    6/17/2025$49.00Outperform
    Wolfe Research
    3/31/2025$50.00Buy
    Redburn Atlantic
    10/16/2024Sector Outperform
    Scotiabank
    10/3/2024Perform
    Oppenheimer
    9/4/2024$46.00Overweight
    Piper Sandler
    3/21/2024$45.00Outperform
    Raymond James
    1/31/2024$37.00Market Perform
    BMO Capital Markets
    12/8/2023$58.00Overweight
    Wells Fargo
    More analyst ratings